Robert Shin, MD, FAAN

home / authors / robert-shin-md-faan

Articles

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 26th 2023

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.

The Unmet Needs in NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 26th 2023

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Approaches to NMOSD Treatment in Clinical Practice

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 26th 2023

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Use of FDA Approved Disease-Modifying Therapies vs Other Treatments in NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 19th 2023

Neurology experts expand on advantages and disadvantages of using FDA-approved treatment compared with other therapy options for neuromyelitis optica spectrum disorder.

Effects of Polymorphism in the Use of Anti-CD19 and Anti-CD20 B-cell Therapy in NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 19th 2023

Robert Shin, MD, FAAN, discusses the potential advantages of using inebilizumab over rituximab in the treatment of NMOSD.

Safety Considerations for Therapies in NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 12th 2023

With a plethora of new treatments for NMOSD, a panel discusses safety concerns.

Recent Approvals for NMOSD Treatment

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 12th 2023

Experts in neurology discuss newly approved medications in the treatment of neuromyelitis optica spectrum disorder, including inebilizumab, eculizumab, and satralizumab.

Treatment Selection in NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 5th 2023

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller discuss the current neuromyelitis optica spectrum disorder treatment landscape.

Initiating Treatment and Goals of Therapy for NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

April 5th 2023

Expert neurologists review treatment goals in patients with neuromyelitis optica spectrum disorder and share insights on long-term disease-modifying therapies.

Progression of NMOSD Over Time

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

March 29th 2023

Experts in neurology discuss the progression of neuromyelitis optica spectrum disorder, focusing on acute relapse and pseudo attacks.

Pathophysiology of NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

March 29th 2023

Aaron Miller, MD, FAAN, reviews the pathophysiology of neuromyelitis optica spectrum disorder and the role of aquaporin-4 in the disease pathway.

Differential Diagnosis and Types of NMOSD

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

March 22nd 2023

Flavia Nelson, MD, and Robert Shin, MD, FAAN, provide insight on the forms of neuromyelitis optica spectrum disorder and how its attacks differ from multiple sclerosis.

Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

March 22nd 2023

Aaron Miller, MD, FAAN, provides an overview of neuromyelitis optica spectrum disorder (NMOSD).